Partner pages

Partner briefs for APA 2026 booth conversations and ongoing pharma engagements. Each page is tailored using context, talking points, and the Videra fit for that specific program.

• - Life Sciences Overview PLATFORM
  Educational overview · What Videra does, end-to-end across trial & commercial
  →
• - Bretisilocin
  AbbVie · GM-2505 · MDD · Phase 2
  →
• - ALA-3000
  Alar · Long-acting ketamine · TRD · Phase 1
  →
• - COMP360
  COMPASS · Psilocybin · TRD · NDA rolling review
  →
• - Spravato
  J&J · Esketamine · TRD/MDD · Commercial
  →
• - TSND-201
  Transcend Therapeutics · Methylone · PTSD · Phase 3
  →
• - Aydia
  Solvonis · MDMA derivative · PTSD · Early clinical
  →
• - TACT-411 / 833
  Tactogen · Next-gen entactogens · Preclinical/Phase 1
  →
• - AM1002
  Arcadia Medicine · Non-racemic MDMA · PTSD · Preclinical
  →
• - NYPRG-101
  Curuvia · BOL-148 · Cluster HA / 5-HT2A · Phase 1/2
  →
• - BETR-001
  BetterLife Pharma · BOL-148 · Cluster headache · Phase 2
  →
• - REDI
  Reconnect Labs · SL DMT + harmine · Depression/PTSD · Phase 1
  →
• DEEPER DIVE · DETAILED VERSIONS
• - TSND-201 v2 · DETAILED
  Transcend Therapeutics · Methylone · PTSD · Phase 3
  →
• - Aydia v2 · DETAILED
  Solvonis · MDMA derivative · PTSD · Early clinical
  →
• - TACT-411 / 833 v2 · DETAILED
  Tactogen · Next-gen entactogens · Preclinical/Phase 1
  →
• - AM1002 v2 · DETAILED
  Arcadia Medicine · Non-racemic MDMA · PTSD · Preclinical
  →
• - NYPRG-101 v2 · DETAILED
  Curuvia · BOL-148 · Cluster HA / 5-HT2A · Phase 1/2
  →
• - BETR-001 v2 · DETAILED
  BetterLife Pharma · BOL-148 · Cluster headache · Phase 2
  →
• - REDI v2 · DETAILED
  Reconnect Labs · SL DMT + harmine · Depression/PTSD · Phase 1
  →
• APA 2026
• - Ansofaxine
  Luye Pharma USA · Major Depressive Disorder · Phase 3 (completed primary end
  →
• - Seltorexant
  J&J · MDD with insomnia symptoms (adjunctive t · Phase 3 (positive results)
  →
• - Relexxii
  Vertical Pharmaceuticals · ADHD (adults & pediatric 6+) · APPROVED (2022)
  →
• - AZSTARYS
  Zevra Pharmaceuticals · ADHD (6+ years) · APPROVED (2021)
  →
• - VQW-765
  Vanda Pharmaceuticals · Social Anxiety Disorder · Phase 3 (initiated 2026)
  →
• - Subvenite
  OWP Pharmaceuticals · Bipolar I Disorder maintenance (delay mo · APPROVED (Sept 2025)
  →
• - Bysanti
  Vanda Pharmaceuticals · Bipolar I Disorder; Schizophrenia (both · APPROVED (2026) + Phase 3 TRD-
  →
• - FL-100
  Flow Neuroscience · Major Depressive Disorder (moderate to s · FDA APPROVED (Jan 2026) — laun
  →
• - WAKIX
  Harmony Biosciences · Narcolepsy: Excessive Daytime Sleepiness · APPROVED
  →
• - Cobenfy
  BMS · Schizophrenia (approved Sept 2024); Phas · APPROVED + Phase 3 expansions
  →
• - Vraylar
  AbbVie · Schizophrenia; Bipolar I disorder (manic · APPROVED
  →
• - Nuplazid
  Acadia Pharmaceuticals · Parkinson's Disease Psychosis (PDP) · APPROVED
  →
• - Auvelity
  Axsome Therapeutics · Major Depressive Disorder (approved); Al · APPROVED (MDD) + sNDA for AD A
  →
• - Caplyta
  J&J · Schizophrenia; Bipolar I/II Depression; · APPROVED
  →
• - Erzofri
  Luye Pharma USA · Schizophrenia; Schizoaffective Disorder · APPROVED
  →
• - Rykindo
  Luye Pharma USA · Schizophrenia; Bipolar I Disorder mainte · APPROVED
  →
• - Qelbree
  Supernus Pharmaceuticals · ADHD (pediatric 6-17; adult) · APPROVED
  →
• - Fanapt
  Vanda Pharmaceuticals · Schizophrenia (2009); Bipolar I Disorder · APPROVED
  →
• - Daybue
  Acadia Pharmaceuticals · Rett Syndrome (adults & pediatric 2+) · APPROVED
  →
• - Prozac
  Lilly · MDD, OCD, Panic Disorder, Bulimia (Proza · APPROVED (legacy/generic)
  →
• - Solriamfetol
  Axsome Therapeutics · ADHD (Phase 3 FOCUS met primary endpoint · Phase 3 (multiple trials)
  →